Health Condition 1: I422- Other hypertrophic cardiomyopathy
Conditions
Interventions
Intervention1: NIL: NIL
Control Intervention1: NIL: NIL
Sponsors
Bristol-Myers Squibb India Pvt. Ltd.
Eligibility
Inclusion criteria
Inclusion criteria: 1. Patients aged 18 years or more with established diagnosis of HCM at study enrollment (cross sectional survey) or at index date (retrospective). 2. Patients or their caregiver (authorized representative) who are willing and able to sign ICF (cross-sectional survey). 3. Patients with a minimum of 12 months follow-up after index date (retrospective).
Exclusion criteria
Exclusion criteria: 1. Patients with no EHRs data available (retrospective). 2. Patients with clinical conditions that mimic HCM (such as amyloidosis, hemochromatosis, sarcoidosis, Fabry disease, etc).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary objective is to assess the clinical burden (patient s demographic characteristics, HCM diagnosis, HCM symptoms, NYHA classification, treatment and monitoring, medical history, and fatal CV complications) of HCM (including patients with obstructive HCM and non-obstructive HCM) in India using electronic health records (EHRs) and patient questionnairesTimepoint: 1 year ( 52 Weeks) | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. To assess annualized health care resource utilization (HCRU) & associated costs of HCM (including patients with obstructive HCM & non-obstructive HCM) in India using patient, health care professional (HCP), & procurement staff questionnaires.Timepoint: 1 year (52 Weeks);2. To assess health related quality of life (HRQoL) in patients with HCM (including patients with obstructive HCM & non-obstructive HCM) in India using patient questionnaires.Timepoint: 1 year ( 52 Weeks) | — |
Countries
India
Contacts
Public ContactJason Williams
Bristol-Myers Squibb India Pvt. Ltd.
Outcome results
None listed